The next act for a biotech rainmaker
Novo Nordisk can barely make enough of Wegovy to satisfy demand for the dramatically effective obesity treatment. But scientists in the company’s research ranks are already at work on a…
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hello, everyone. Damian here with an explanation of the latest trend in biotech financing, a big idea in oncology, and Novo Nordisk’s plans to make Wegovy obsolete.
What's Your Reaction?
